|
Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial. |
| |
|
Leadership - PFS Genomics |
Stock and Other Ownership Interests - PFS Genomics |
Consulting or Advisory Role - Dendreon; EMD Serono; Ferring; Janssen Oncology; Sanofi |
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst) |
| |
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
| |
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
| |
|
No Relationships to Disclose |
| |
|
Employment - Janssen Oncology |
Stock and Other Ownership Interests - Janssen Oncology |
Research Funding - Janssen Oncology |
Travel, Accommodations, Expenses - Janssen Oncology |
| |
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
| |
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
| |
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
| |
|
Stock and Other Ownership Interests - Xing Technologies |
Honoraria - Ipsen; Janssen Oncology; Medivation/Astellas; Merck; Novartis; Pfizer; Roche/Genentech |
Consulting or Advisory Role - Pfizer |
Speakers' Bureau - Ipsen; Janssen Oncology; Medivation/Astellas; Merck; Novartis; Pfizer; Roche/Genentech |
Research Funding - Merck KGaA |
Patents, Royalties, Other Intellectual Property - 4 patents on nanotechnology |
Travel, Accommodations, Expenses - Ipsen; Janssen Oncology; Medivation/Astellas; Merck; Novartis; Pfizer; Roche/Genentech |
| |
|
Honoraria - Bayer; Janssen; Sanofi |
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Janssen |
Research Funding - Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Janssen (Inst); Pfizer (Inst); Tokai Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Bayer; Ipsen; Janssen |
| |
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Sanofi |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Janssen Oncology (Inst); Sanofi (Inst) |
| |
|
Honoraria - Clovis Oncology; Novartis |
Consulting or Advisory Role - Astellas Pharma; Bayer; Clovis Oncology; Janssen-Cilag; Pfizer |
Speakers' Bureau - Pfizer |
Research Funding - Sanofi/Aventis (Inst) |
| |
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Lightpoint Medical |
Research Funding - Astellas Pharma; Bristol-Myers Squibb; German Cancer Aid (I); German Research Foundation; Janssen; Profound Medical |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen |
| |
|
|
Stock and Other Ownership Interests - GenomeDx |
Patents, Royalties, Other Intellectual Property - GenomeDx |
| |
|
|
|
Stock and Other Ownership Interests - GenomeDx |
Patents, Royalties, Other Intellectual Property - CANCER DIAGNOSTICS USING BIOMARKERS 20140066323 |
Travel, Accommodations, Expenses - GenomeDx |
| |
|
|
| |
|
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics |
|
Consulting or Advisory Role - Fortis; Janssen Oncology |
Research Funding - Janssen (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - Janssen |
| |
|
Consulting or Advisory Role - Amgen; Bayer; Janssen Oncology; Pfizer |
Research Funding - Bayer (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst) |